¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dermic graft"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • composite graft
    º¹ÇÕÀ̽Ä, º¹ÇÕÁ¶Á÷À̽Ä
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ¼ú, ½ÉÀ嵿¸Æ¿ìȸ¼ú
  • costal cartilage graft
    °¥ºñ¿¬°ñÀ̽Ä, ´Á¿¬°ñÀ̽Ä
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷À̽Ä
  • cartilage graft
    ¿¬°ñÀÌ½ÄÆí
  • chorioallantoic graft
    À¶¸ð¿ä¸·À̽Ä
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • free graft
    À¯¸®ÀÌ½ÄÆí
  • free jejunal graft
    À¯¸®ºóâÀÚÀ̽Ä(¼ú), À¯¸®°øÀåÀ̽Ä(¼ú)
  • full-thickness graft
    ÀüÃþÇǺÎÀ̽Ä
  • gauntlet graft
    Àå°©¸ð¾çÀ̽İñÆí
  • graft
    1. ÀÌ½Ä 2. ÀÌ½ÄÆí
  • graft atherosclerosis
    ÀÌ½ÄÆíÁ×°æÈ­(Áõ), ÀÌ½ÄÆíÁ׸ð¾ç°æÈ­(Áõ)
  • graft recipient
    1. ÀÌ½ÄÆí¹Þ´ÂÀÌ 2. ÀÌ½ÄÆí¹Þ´ÂºÎÀ§
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • composite graft
    º¹ÇÕÀ̽Ä, º¹ÇÕÁ¶Á÷À̽Ä
  • coronary artery bypass graft
    ½ÉÀ嵿¸Æ¿ìȸ¼ú
  • costal cartilage graft
    °¥ºñ¿¬°ñÀ̽Ä, ´Á¿¬°ñÀ̽Ä
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷À̽Ä
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • graft-versus-host disease
    À̽Ĵë¼÷ÁÖº´
  • free graft
    À¯¸®À̽Ä
  • free jejunal graft
    À¯¸®ºóâÀÚÀ̽ļú, À¯¸®°øÀåÀ̽ļú
  • full-thickness graft
    ÀüÃþÇǺÎÀ̽Ä
  • graft
    À̽Ä, ÀÌ½ÄÆí
  • gauntlet graft
    Àå°©¸ð¾çÀ̽İñÆí
  • graft recipient
    ÀÌ½ÄÆí¹Þ´ÂÀÌ
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ
  • graft schizophrenia
    (¢¡propf schizophrenia) À̽ÄÁ¤½ÅºÐ¿­º´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • graft accordion
    ¾ÆÄÚ¿Àµð¾ð½Ä ½ÄÇÇ(¡­ãÕù«).
  • graft atherosclerosis
    À̽ÄÁ×»ó°æÈ­Áõ.
  • graft atherosclerosis
    À̽ÄÁ×»ó°æÈ­Áõ.
  • graft polymer
    À̽ÄÁßÇÕü.
  • graft recipient
    ÀÌ½ÄÆí¼ö·ÉÀÚ(ì¹ãÕø¸áôçÐíº).
  • graft recipient
    ÀÌ½ÄÆí¼ö·ÉÀÚ(ÀÌ½ÄÆí¼ö¿µÀÚ).
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ).
  • graft rejection, white
    ¹é»öÈ­ ÀÌ½ÄÆí°ÅºÎ (Ãʱ޼º)
  • graft schizophrenia See schizophrenia
    Á¢Áö<Á¢¸ñ>Á¤½ÅºÐ¿­º´<Áõ> (ïÈò«<ïÈÙÊ>ïñãêÝÂæñÜ»<ñø>)
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft, free jejunal
    À¯¸®°øÀå À̽ļú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • corneal graft
    °¢¸·ÀÌ½ÄÆí(¡­ì¹ãÖ).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷ À̽Ä
  • dermis graft
    ÁøÇÇÀ̽Ä
  • double-end graft
    ½Ö´ÜÀ̽Ä.
  • dural graft
    °æ¸·À̽Ä(°æ¸·À̽Ä).
  • epidermic graft
    Ç¥ÇÇÀ̽Ä(¡­ì¹ãÕ).
  • fascia graft
    ±Ù¸· À̽Ä(ÐÉØ¯ì¹ãÕ).
  • fat graft
    Áö¹æÀÌ½ÄÆí(¡­ÀÌ½ÄÆí).
  • fat graft
    Áö¹æÀ̽Ä
  • fat graft
    Áö¹æÀÌ½ÄÆí(¡­ì¹ãÕø¸).
  • free graft
    À¯¸®À̽Ä(ë´ìÆì¹ãÕ).
  • free graft
    À¯¸®À̽Ä(À¯ÀÌÀ̽Ä).
  • free jejunal graft
    À¯¸®°øÀå À̽ļú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACBG aortocoronary bypass graft
ACG accelerator globulin; alternative care grant; ambulatory care group; American College of Gastroenter...
ACSVBG aortocoronary saphenous vein bypass graft
AFBG aortofemoral bypass graft
BG basal ganglion; basic gastrin; Bender Gestalt [test]; beta-galactosidase; beta-glucuronidase; bicolo...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CABG Coronary Artery Bypass Graft surgery
DGF Delayed graft function
GVHD Graft Versus Host Disease
GvHR Graft v Host Reaction
GVD Graft vascular disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dural graft
    °æ¸· À̽Ä
  • epidermic graft
    Ç¥ÇÇ À̽Ä, Ç¥ÇÇ ÀÌ½ÄÆí
    ¸Ç»ì¿¡ ÀÌ½ÄµÈ Ç¥ÇÇ Æí.
  • Esser graft
    ¿§¼¼¸£ ÀÌ½Ä Æí
    StentÀÇ ÁÖÇü À§¿¡ ÀÌ½Ä ÇǺθ¦ Æì¼­ ÀÌ½Ä Æí°ú ÁÖÇüÀ» ºÀÇÕÇϰí À̸¦ ¸¸µé¾îÁø Æ÷ÄÏ ¼Ó¿¡ ³Ö´Â ÀÏÁ¾ÀÇ ÀüÃþ ÇǺΠÀÌ½Ä Æí.
  • fascia graft
    ±Ù¸· À̽Ä, ±Ù¸· ÀÌ½ÄÆí
    ´ëÅð ±Ù¸· ¶Ç´Â ¿äÃß ±Ù¸·À¸·ÎºÎÅÍ ¾òÀº ÀÌ½Ä Á¶Á÷.
  • fat graft
    Áö¹æ ÀÌ½ÄÆí, Áö¹æ À̽Ä
    ÁöÁö Á¶Á÷¿¡¼­ ¿ÏÀüÈ÷ À¯¸®½ÃŲ Áö¹æÀÇ À̽Ä. ÇÔ¸ôºÎ¸¦ ¸Þ¿ì±â À§ÇØ »ç¿ëÇÑ´Ù.
  • full thickness graft
    ÀüÃþ ÇǺΠÀÌ½ÄÆí, ÀüÃþ ½ÄÇÇ
  • heterodermic graft
    ÀÌÁ¾ ÇǺΠÀÌ½ÄÆí
    ÀÌÁ¾ µ¿¹°¿¡¼­ ¾òÀº ÇǺΠÀÌ½ÄÆí.
  • heterologous graft
    ÀÌÁ¾ À̽Ä
    ÀÌÁ¾ÀÇ µ¿¹°°£¿¡ À̽ĵǴ Á¶Á÷Æí.
  • hyperplastic graft
    Áõ½Ä¼º À̽Ä
    ¿°ÁõÀ¸·ÎºÎÅÍ È¸º¹ÇÏ´Â »óÅÂ¿Í °°Àº Ȱµ¿Àû º¹¿ø »óÅ¿¡¼­ÀÇ ÇǺΠÀ̽Ä.
  • inlay bone graft
    °¨ÀÔ °ñ À̽Ä
  • lamellar graft
    ÃþÆÇ À̽Ä
    ºÒÅõ¸íÇÑ °¢¸·ÀÇ Ç¥ÃþÀ» Á¦°ø ¾ÈÀÇ Åõ¸íÇÑ °¢¸·ÀÇ ¹ÚÃþ°ú ¹Ù²Ù´Â À̽Ä.
  • muscle graft
    ±ÙÀ° À̽Ä
  • Ollier-Thiersch graft
    ¿Ã¸®¿¡¸£ Ƽ¸£½¬ ÀÌ½ÄÆí
    »óÇÇÃþ, »óÇǸÁ, ÁøÇÇÀÇ ÀϺθ¦ Æ÷ÇÔÇÑ ¸Å¿ì ¾ã°í ³ÐÀº ÇǺΠÀÌ½ÄÆí.
  • omental graft
    ´ë¸Á À̽Ä
    ºÀÇÕ¼±À» µ¤±â À§ÇÏ¿© »ç¿ëµÇ´Â À¯¸®µÇ°Å³ª Àý´ÜµÇÁö ¾ÊÀº ´ë¸ÁÀÇ ºÐÀý. À§Àå ¹× °áÀå ¼ö¼ú ÈÄ¿¡ »ç¿ëµÈ´Ù.
  • onlay bone graft
    ÁßÃþ°ñ ÀÌ½ÄÆí
    ÇÇÀ̽ÄÀÚÀÇ ÇÇÁú¼º °ñ À§¿¡ µ¤´Â ÀÌ½ÄÆíÀ¸·Î¼­ÀÇ »À.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
bypass graft <surgery> An alternative blood vessel that is created by a surgeon to reroute blood flow. Grafts may be synthetic (dacryon) or autologous (a vein from the patients own leg used as a substitute for the diseased vessel).
(20 Mar 1998)
cable graft A multiple strand nerve graft arranged as a pathway for regeneration of axons.
(05 Mar 2000)
vascularised graft The state of a graft after the recipient vasculature has been connected with the vessels in the graft.
(05 Mar 2000)
partial-thickness graft A graft of portions of the skin, i.e., the epidermis and part of the dermis, or of part of the mucosa and submucosa, but not including the periosteum.
Synonym: partial-thickness graft, split-skin graft.
(05 Mar 2000)
pedicle graft A skin flap sustained by a blood-carrying stem from the donor site during transfer, in periodontal surgery, a flap used to increase the width of attached gingiva, or to cover a root surface, by moving the attached gingiva, which remains joined at one side, to an adjacent position and suturing the free end.
(05 Mar 2000)
Reverdin graft Small bits of skin, of partial or full thickness, removed from a healthy area and seeded in a site to be covered.
Synonym: Reverdin graft.
(05 Mar 2000)
graft To insert scions from one tree, or kind of tree, etc, into another; to practice grafting.
A small shoot or scion of a tree inserted in another tree, the stock of which is to support and nourish it. The two unite and become one tree, but the graft determines the kind of fruit.
A branch or portion of a tree growing from such a shoot.
<surgery> A portion of living tissue used in the operation of autoplasty.
Origin: OE. Graff, F. Greffe, originally the same word as OF. Grafe pencil, L. Graphium, Gr, fr. To write; prob. Akin to E. Carve. So named from the resemblance of a scion or shoot to a pointed pencil. Cf. Graphic, Grammar.
1. To insert (a graft) in a branch or stem of another tree; to propagate by insertion in another stock; also, to insert a graft upon. [Formerly written graff.
2.
<surgery> To implant a portion of (living flesh or akin) in a lesion so as to form an organic union.
3.
To join (one thing) to another as if by grafting, so as to bring about a close union. "And graft my love immortal on thy fame !" (Pope)
4.
To cover, as a ring bolt, block strap, splicing, etc, with a weaving of small cord or rope-yarns.
Origin: F. Greffer. See Graft.
Source: Websters Dictionary
(01 Mar 1998)
graft enhancement, immunologic The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
(12 Dec 1998)
graft occlusion <physiology> Obstruction of flow in biological or prosthetic vascular grafts.
(12 Dec 1998)
graft rejection <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take.
(16 Dec 1997)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
mesh graft A skin graft in which multiple slits have been made, so it can be stretched to cover a large area.
Synonym: mesh graft.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á